ACD's TKInsight? - Outsmarting Drug Resistance

Gleevec was the silver bullet. When 诺华 introduced Gleevec (imatinib) in 2001, it was hailed as a "miracle drug" in the fight against cancer. The first-in-class TKI targeted the BCR-ABL fusion, a key driver of Chronic Myeloid Leukemia - a deadly blood cancer that killed 70% of patients within 5 years. Gleevec reduced CML's mortality to just 17%. But a major hurdle emerged: Some patients developed mutations in the BCR-ABL gene, rendering them resistant to Gleevec. Using computational and structure-based design, Iclusig (ponatinib) was created to bind to a broad spectrum of mutations, including the notorious T315I mutation behind Gleevec resistance. Iclusig saved the day - but over a decade passed before ARIAD Pharmaceuticals, Inc. 's 3rd Generation TKI came out. How many lives were lost while the world waited for a breakthrough?

Enter Advanced Cellular Dynamics, Inc. 's TKInsight? Prospective Mutagenesis?- a powerful tool to optimize Next-Gen TKI development.

• Stay Ahead of the Curve:?Learn if – and where – mutations may occur and design your Next-Gen TKIs to adapt.
• Uncover Companion Therapy Opportunities:?Identify vulnerabilities in mutated cells and develop companion drugs to target those weaknesses.
• Reduce TKI Timelines:?By anticipating resistance mechanisms, you can avoid costly dead ends and streamline your development pipeline.

Why ACD is the perfect partner for your TKI pipeline:

• Exclusive:?Leverage ACD's unique expertise and proprietary tools: TKInsight?, The KERC Database?, KinoScope? and Kinocore?.
• Actionable Insights: Gain a deeper understanding of resistance mechanisms for smarter decision-making.
• Proven Track Record:?Collaborate with a leader, trusted by over 100 companies including 8 of the top 11 biopharma giants.

Outsmart Resistance: Predict and Prevail with ACD's TKInsight

Contact Advanced Cellular Dynamics, Inc. to Learn More About TKInsight!

#Biotech #Innovation #CancerResearch #TKIResistance #NextGenTKI?

Advanced Cellular Dynamics, Inc. - Discovery Starts Here!